Applications of Boc-(S)-3-Amino-4-(4-Methyl-Phenyl)-Butyric Acid in Industrial Manufacturing

Boc-(S)-3-Amino-4-(4-Methyl-Phenyl)-Butyric Acid plays a critical role as a protected chiral intermediate in multiple industrial synthesis processes, offering reliable performance in regulated manufacturing environments. The following sectors represent the primary real-world applications where this raw ingredient directly contributes to downstream specialty manufacturing.

1. Peptide Active Pharmaceutical Ingredient (API) Synthesis

Pharmaceutical peptide producers rely on this chiral intermediate for the stepwise construction of advanced peptide APIs, particularly where stringent optical purity and traceability are mandatory. It serves as a building block in solid phase peptide synthesis, maintaining stereochemical integrity and process consistency from pilot to commercial scale. Downstream users achieve high batch reproducibility and meet current global regulatory filings.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• USP, EP, and JP monograph purity benchmarks
• FDA DMF (Drug Master File) referencing
• EU REACH registration and traceability requirements

Typical usage ratio

• Employed at 1.05–1.25 molar equivalents per coupling cycle, with ratio optimized by target peptide length, resin loading, and risk of byproduct formation

Downstream process integration

• Introduced at the protected amino acid feed stage, often dissolved in DMF or NMP, coupled to resin-bound or solution-phase growing peptide chains via standard carbodiimide or uronium-mediated chemistry

Final product types

• GMP-grade peptide APIs for endocrine, cardiovascular, and oncology indications
• Sterile peptide drug substances
• Research-grade peptide fragments for structure-activity studies

2. Chiral Intermediate for CNS Small Molecule Drug Synthesis

Manufacturers of central nervous system (CNS) pharmaceuticals utilize this protected acid in the construction of advanced chiral intermediates for small molecule drugs, where maintaining the precise stereochemistry at the 3-amino position is critical for downstream pharmacological activity. Custom synthesis teams use this material to meet strict batch-to-batch purity specifications required by innovator and generic drug pathways.

Industry compliance standards

• 21 CFR Part 211 (cGMP for Finished Pharmaceuticals)
• ICH Q3A/B impurity limits for APIs
• Pharmaceutical quality systems per ISO 9001:2015 and ISO 14001

Typical usage ratio

• Typically dosed at 0.9–1.2 equivalents per key coupling or reductive amination step, with molar balance adjusted according to the enantiopurity target and subsequent deprotection steps

Downstream process integration

• Incorporated after Boc deprotection to generate free amine which is then functionalized via alkylation, acylation, or used in complex ring closure for CNS-active molecules

Final product types

• Chiral intermediates for dopamine modulators and 5-HT receptor antagonists
• Precursor building blocks for generic CNS drugs
• GMP APIs for antidepressant and antiepileptic products

3. Synthesis of Dipeptide and Dipeptidomimetic Building Blocks

Chemical manufacturers engaged in supplying specialty dipeptide and peptidomimetic libraries adopt this raw material to enable regioselective chain elongation while maintaining protection of sensitive amine functionalities. Its application ensures minimized epimerization during chain extension, supporting the production of high-purity research materials and pilot-scale scaffolds for pharmaceutical partners.

Industry compliance standards

• ISO 13485:2016 (applicable to diagnostic and research reagents)
• GLP (Good Laboratory Practice) for non-clinical use
• FDA Quality System Regulation for Research Use Only (RUO) substances

Typical usage ratio

• Applied at stoichiometric ratios (1.0–1.1 equivalents) relative to carboxylic acid or amine partners, adjusted for solubility and peptide chain length considerations

Downstream process integration

• Utilized in mixed anhydride or preactivated ester coupling strategies to form dipeptides or substituted peptidomimetics, followed by stepwise deprotection

Final product types

• Research dipeptide libraries for medicinal chemistry
• Lead compounds and SAR exploration panels
• Diagnostic peptide probes for bioanalytical assays

4. Protected Amino Acid Supply for Oligopeptide Diagnostic Reagents

Producers of synthetic oligopeptide controls and assay reagents in the in vitro diagnostics (IVD) sector include this protected amino acid in their portfolios to deliver batch-homogeneous, sequence-defined materials with controlled side chain stereochemistry. The material’s Boc group allows precise removal directly prior to functionalization, crucial for conjugation and labeling applications where purity impacts assay performance.

Industry compliance standards

• ISO 13485:2016 (Medical Devices—Quality Management Systems)
• CLSI IVD standards
• REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) for EU market

Typical usage ratio

• Utilized at 0.95–1.1 equivalents per step in automated peptide synthesis platforms, with the excess controlled to limit carryover into cleaved product fractions

Downstream process integration

• Loaded directly onto solid supports for elongation; Boc group is removed under acidolysis immediately prior to further amino acid coupling or conjugative labeling

Final product types

• Synthetic oligopeptide calibration standards
• Labeled peptide probes for diagnostic kits
• Reference peptides for mass spectrometry and immunoassays

5. Chiral Synthon for Advanced Agrochemical Discovery

Agrochemical research laboratories incorporate this compound as a chiral synthon to generate advanced intermediates for selective enzyme inhibitors and regulatory probes aimed at crop protection formulations where stereochemically defined scaffold is required in screening and lead optimization. The protected amino group allows for controlled reaction introduction and subsequent modification as part of candidate structure diversification.

Industry compliance standards

• EPA TSCA chemical inventory compliance
• OECD Good Laboratory Practice for non-clinical use
• ISO 9001:2015 quality management

Typical usage ratio

• Commonly dosed at 1.0–1.3 molar equivalents per key coupling or amidation step, depending on the downstream functionalization scope

Downstream process integration

• Engaged during construction of chiral building blocks, often with iterative deprotection and derivatization schemes for SAR agrochemical programs

Final product types

• Agrochemical lead compounds for proprietary crop solutions
• Enzyme inhibition assay substrates
• Screening libraries for regulatory approval studies